Protein / target
Kinesin-1 heavy chain
Protein at a glance
Biological role
Plus-end-directed microtubule motor activity
Primary system
Nervous system
Strongest disease association
kyphomelic dysplasia
Therapeutic maturity
Clinically validated target
Druggability
Small molecule
Clinical development
2 approved
Derived from structured UniProt, Open Targets and literature data on this page.
Protein profile
Canonical identity and biological annotation from UniProt.
Function
Microtubule-dependent motor required for normal distribution of mitochondria and lysosomes. Can induce formation of neurite-like membrane protrusions in non-neuronal cells in a ZFYVE27-dependent manner (By similarity). Regulates centrosome and nuclear positioning during mitotic entry. During the G2 phase of the cell cycle in a BICD2-dependent manner, antagonizes dynein function and drives the separation of nuclei and centrosomes (PubMed:20386726). Required for anterograde axonal transportation of MAPK8IP3/JIP3 which is essential for MAPK8IP3/JIP3 function in axon elongation (By similarity). Through binding with PLEKHM2 and ARL8B, directs lysosome movement toward microtubule plus ends (Probable). Involved in NK cell-mediated cytotoxicity. Drives the polarization of cytolytic granules and microtubule-organizing centers (MTOCs) toward the immune synapse between effector NK lymphocytes and target cells (PubMed:24088571)
Subcellular location
Domains and Gene Ontology detail (40)Hide
Domains & features
Gene Ontology
- Caxon cytoplasm
- Cciliary rootlet
- Ccytolytic granule membrane
- Ccytoplasm
- Ccytosol
- Cdendrite cytoplasm
- Ckinesin complex
- Cmembrane
- Cmicrotubule
- Cmitochondrion
- Cperinuclear region of cytoplasm
- Cphagocytic vesicle
Biological roles
What this protein does, drawn together from its UniProt function, Gene Ontology terms and Reactome pathways.
View supporting evidenceHide supporting evidence
Synaptic signalling
- ·Microtubule-dependent motor required for normal distribution of mitochondria and lysosom…
- ·postsynaptic cytosol
- ·anterograde dendritic transport of neurotransmitter receptor complex
- ·positive regulation of synaptic transmission, GABAergic
Immune signalling
- ·Microtubule-dependent motor required for normal distribution of mitochondria and lysosom…
- ·MHC class II antigen presentation
- ·Processing of antigen in germinal center B cells
Inhibitory neurotransmission
- ·positive regulation of synaptic transmission, GABAergic
View underlying pathways (7)Hide underlying pathways
Concepts derived from UniProt GO Reactome — each badge above shows which sources supported that role.
Interaction neighbourhood
Proteins with the strongest functional or physical association. Node size and line weight reflect STRING confidence; hover or select a partner to inspect one association.
Functional and physical associations from STRING v12.0. Only associations with this protein are drawn — partner-to-partner links are not part of this evidence.
Drugs targeting this protein
Whether each drug engages this protein directly or through a complex, and how many other targets are recorded for it. Direct binders with few recorded targets are listed first.
Kinesin-1 heavy chain/ Tyrosine-protein kinase receptor RET inhibitor
Appears in clinical studies involving medullary thyroid gland carcinoma, non-small cell lung carcinoma, non-small cell lung carcinoma, neoplasm
ChEMBL mechanism, action type and target identity. Open Targets clinical status and indications.
Translational evidence
Why this target matters therapeutically — disease associations, drugs in development, tractability and safety, from Open Targets.
Strongest genetic associations
Human genetic evidence — the most direct causal link between this target and a disease.
Highest-confidence therapeutic associations
Diseases where a drug acting on this target has already reached clinical development.
Highest overall evidence
Remaining associations by Open Targets' aggregated evidence score.
Show all associationsHide all associations
Open Targets ranks 321 associations for this target and we store the top 10 by aggregated score. The long tail is largely literature co-mention and RNA-expression evidence, not evidence that this target drives those diseases.
Known drugs · 2 total
medullary thyroid gland carcinoma · non-small cell lung carcinoma · non-small cell lung carcinoma
medullary thyroid gland carcinoma · non-small cell lung carcinoma · thyroid cancer
Tractability
Clinical trials
Trials of drugs that target this protein — reached indirectly through those drugs, so a trial listed here studies the drug, not the protein.
Show remaining trials (5)Hide
ClinicalTrials.gov via the drug-target graph.
Forefront confidence
Our own weighting of the evidence behind each disease association. Human genetics and clinical evidence count for most; literature co-mention counts for little, because two entities sharing an abstract is not evidence that one drives the other.
The evidence agreement range shows how closely the independent evidence families agree — it is not a statistical confidence interval, and nothing here is fitted to outcome data. Derived from Open Targets evidence types under Forefront weighting; the underlying per-type scores are shown above so the calculation can be checked.
What's happening now
Recent activity around this target, drawn from one canonical event stream. Every item is reached through a drug that targets this protein, so each event is news about that drug rather than about the protein directly.
- Withdrawn from market
Market withdrawal: Gavreto (EMA)
- New publicationPralsetinib in Patients with Advanced/Metastatic Rearranged During Transfection (RET)-Altered Thyroid Cancer: Updated Efficacy and Safety Data from the ARROW Study.
Objective event titles are shown unmodified; the event kind and significance line are derived from structured fields. Forefront AttentionEvent stream aggregating Europe PMC Regulatory filings ClinicalTrials.gov.